Yvonne Personke

Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase <scp>IIIb</scp> randomized, double‐blind, parallel‐group, <scp>GUIDE</scp> study

Knut Schäkel, Kristian Reich, K. Asadullah et al. · Journal of the European Academy of Dermatology and Venereology · 2023 · 100 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +17

Real‐world effectiveness of guselkumab in patients with psoriasis: Health‐related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial

Sascha Gerdes, Beate Bräu, Matthias Hoffmann et al. · The Journal of Dermatology · 2021 · 47 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Real‐world evidence from the non‐interventional, prospective, German multicentre <scp>PERSIST</scp> study of patients with psoriasis after 1 year of treatment with guselkumab

Sascha Gerdes, K. Asadullah, Matthias Hoffmann et al. · Journal of the European Academy of Dermatology and Venereology · 2022 · 21 citations · Full text

Medicine, Dermatology, Pharmacotherapy +14

Effectiveness, safety and quality‐of‐life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non‐interventional, prospective, German multicentre <scp>PERSIST</scp> study

Sascha Gerdes, Matthias Hoffmann, K. Asadullah et al. · Journal of the European Academy of Dermatology and Venereology · 2023 · 17 citations · Full text

Medicine, Dermatology, Pharmacotherapy +11